Share on StockTwits

ABIOMED (NASDAQ:ABMD) COO David M. Weber unloaded 10,172 shares of the stock on the open market in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $21.11, for a total value of $214,730.92. Following the sale, the chief operating officer now directly owns 120,310 shares of the company’s stock, valued at approximately $2,539,744. The sale was disclosed in a legal filing with the SEC, which is available at this link.

ABIOMED (NASDAQ:ABMD) traded up 0.84% on Wednesday, hitting $21.71. The stock had a trading volume of 311,856 shares. ABIOMED has a 52-week low of $18.15 and a 52-week high of $30.77. The stock’s 50-day moving average is $22.86 and its 200-day moving average is $26.29. The company has a market cap of $864.3 million and a price-to-earnings ratio of 119.61.

ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings results on Thursday, May 1st. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.01. The company had revenue of $50.40 million for the quarter, compared to the consensus estimate of $50.93 million. During the same quarter in the previous year, the company posted $0.09 earnings per share. The company’s revenue for the quarter was up 15.5% on a year-over-year basis. Analysts expect that ABIOMED will post $0.30 EPS for the current fiscal year.

ABMD has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of ABIOMED in a research note on Thursday, May 15th. They now have a $23.00 price target on the stock. Separately, analysts at Leerink Swann initiated coverage on shares of ABIOMED in a research note on Monday, March 24th. They set an “outperform” rating and a $34.00 price target on the stock. Finally, analysts at BTIG Research upgraded shares of ABIOMED from a “neutral” rating to a “buy” rating in a research note on Friday, March 21st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. ABIOMED currently has a consensus rating of “Buy” and a consensus price target of $26.83.

ABIOMED, Inc is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.